Protocol for a randomized, placebo-controlled, double-blind phase IIa study of the safety, tolerability, and symptomatic efficacy of the ROCK-inhibitor Fasudil in patients with Parkinson's disease (ROCK-PD)

User: Guest

Title:: Protocol for a randomized, placebo-controlled, double-blind phase IIa study of the safety, tolerability, and symptomatic efficacy of the ROCK-inhibitor Fasudil in patients with Parkinson's disease (ROCK-PD)
Document type:: Zeitschriftenaufsatz
Author(s):: Wolff, Andreas W. ; Bidner, Helen ; Remane, Yvonne ; Zimmer, Janine ; Aarsland, Dag ; Rascol, Olivier ; Wyse, Richard K. ; Hapfelmeier, Alexander ; Lingor, Paul
Keywords:: Aging Neuroscience ; Parkinson's disease ; clinical trial ; safety ; tolerability ; symptomatic efficacy ; disease modification ; Fasudil ; ROCK inhibition
Journal title:: Frontiers in Aging Neuroscience
Year:: 2024
Journal volume:: 16
Fulltext / DOI:: doi:10.3389/fnagi.2024.1308577
Publisher:: Frontiers Media S.A.
E-ISSN:: 1663-4365
Date of publication:: 14.02.2024
CC license:: by, https://creativecommons.org/licenses/by/4.0

BibTeX

Occurrences: